As a class of drugs to treat high cholesterol, PCSK9 inhibitors have had trouble gaining tracking in the marketplace.
In a long-running court battle over PCSK9 antibodies, Amgen lost the company’s bid to uphold patent claims for the cholesterol drug Repatha against rival drug Praluent, developed by Sanofi and Regeneron.
Clarivate Analytics pegged 11 drugs set to enter the market during 2020 as potential blockbusters by 2024
Researchers developed a type of nanoparticle that can “eat debris” related to the plaques that cause heart attacks.
Some analysts are checking their crystal balls to get an idea if 2020 will be a busy year for investors, and the early thinking on biotech is yes.
FDA approves expanded label for Praluent"Bad" LDL Cholesterol, Approvals, Biotech, Cardiovascular Events, Cholesterol, Drug Pricing, Expanded Label, FDA, FDA/Regulatory, Heart Attacks, Heterozygous Familial Hypercholesterolemia (HeFH), Injectables, Major Adverse Cardiovascular Events (MACE), PCSK9 inhibitors, Statins, Stroke
The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals’ cholesterol drug Praluent as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.
Sanofi and Regeneron cutting list price of cholesterol drug by 60 percent"Bad" LDL Cholesterol, Biotech, Cholesterol, Congress, Consumers, Costs, Democrats, Donald Trump, Health Insurers, Heart Attacks, House of Representatives, Injectables, Patients, PCSK9 inhibitors, Pricing, Senate, Therapeutics
Sanofi SA and Regeneron Pharmaceuticals Inc. will slash the U.S. list price of the companies’ potent but expensive cholesterol fighter Praluent by 60 percent.
Updated U.S. guidelines on heart health advise more personalized assessment of risk as well as two newer types of cholesterol-lowering drugs for people at particularly high risk of heart attack or stroke.
Amgen Inc., looking to boost use of the U.S. biotechnology company’s potent cholesterol drug Repatha, cut the medication’s U.S. list price by 60 percent to $5,850.
Esperion Therapeutics Inc. said a late-stage trial of the company’s experimental oral drug met the main goal of reducing cholesterol by 28 percent in patients suffering from, or at a high risk of, an artery-clogging heart disease.